Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHASE-I PHASE-II STUDY OF 3TC (LAMIVUDINE) IN HIV-POSITIVE, ASYMPTOMATIC OR MILD AIDS-RELATED COMPLEX PATIENTS - SUSTAINED REDUCTION IN VIRAL MARKERS/
Autore:
INGRAND D; WEBER J; BOUCHER CAB; LOVEDAY C; ROBERT C; HILL A; CAMMACK N; KATLAMA C; TUBIANA R; VALENTIN MA; GENTILINI M; VANLEEUWEN R; DANNER SA; KITCHEN V; MCBRIDE M;
Indirizzi:
HOP LA PITIE SALPETRIERE,CTR ETUD RECH VIROL & IMMUNOL,DEPT MED VIROL,81 BLVD HOP F-75651 PARIS 13 FRANCE ST MARYS HOSP,DEPT GENITOURINARY MED & COMMUNICABLE DIS LONDON ENGLAND UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,ANTIVIRAL THERAPY LAB 1105 AZ AMSTERDAM NETHERLANDS UNIV COLL LONDON,SCH MED,DIV VIROL LONDON W1N 8AA ENGLAND GLAXO RES & DEV LTD GREENFORD MIDDX ENGLAND
Titolo Testata:
AIDS
fascicolo: 12, volume: 9, anno: 1995,
pagine: 1323 - 1329
SICI:
0269-9370(1995)9:12<1323:PPSO3(>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; PLACEBO-CONTROLLED TRIAL; HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE; DOUBLE-BLIND; 2',3'-DIDEOXYINOSINE DDI; AZIDOTHYMIDINE AZT; ZIDOVUDINE AZT; PLASMA VIREMIA; I TRIAL;
Keywords:
HIV INFECTION; PHASE I/II CLINICAL STUDY; LAMIVUDINE; 3TC; CELLULAR VIREMIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
24
Recensione:
Indirizzi per estratti:
Citazione:
D. Ingrand et al., "PHASE-I PHASE-II STUDY OF 3TC (LAMIVUDINE) IN HIV-POSITIVE, ASYMPTOMATIC OR MILD AIDS-RELATED COMPLEX PATIENTS - SUSTAINED REDUCTION IN VIRAL MARKERS/", AIDS, 9(12), 1995, pp. 1323-1329

Abstract

Objective: To evaluate the efficacy of 3TC (lamivudine), a synthetic nucleoside analogue that inhibits HIV reverse transcriptase in vitro, as treatment for HIV-positive, asymptomatic or mild AIDS-related complex patients. Design: Open-label, multinational and multicentre, non-comparative, escalating dose study. Methods: Patients who meet the selection criteria (n = 104) were enrolled in three European countries. Tento 15 patients were included at each of the six dose levels of 3TC (0.5, 1.0, 2.0, 4.0, 8.0, 12.0 and 20.0 mg/kg daily in two divided dosesevery 12 h). Virological parameters - immune-complex dissociation (ICD) assay for HIV p24 antigenaemia, plasma HIV RNA load, whole blood assay and cellular viraemia - were evaluated at weeks 0, 4, 12 and 24. Results: Sustained reductions in HIV RNA load and in ICD p24 antigen levels were observed and maintained over the 12-week assessment period. Greater reductions were noted at higher doses but this trend did not reach statistical significance. In 38 patients, reductions of cell viraemia were significantly greater at 4 weeks for patients treated at higher doses of 3TC. Conclusion: These virological data show that 3TC is a potent inhibitor of HIV replication in HIV-positive, asymptomatic ormild ARC patients as assessed by ICD p24 antigenaemia, plasma HIV RNAload and cell viraemia.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/08/20 alle ore 07:01:58